JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Brian Cheng maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and raises the price target from $46 to $47.
JP Morgan analyst Brian Cheng maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and raises the price target from $46 to $47.